McLeland S M, Lunn K F, Duncan C G, Refsal K R, Quimby J M
Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO.
J Vet Intern Med. 2014 May-Jun;28(3):827-37. doi: 10.1111/jvim.12342. Epub 2014 Mar 14.
Chronic kidney disease (CKD) in cats is associated with gastrointestinal signs commonly attributed to uremic gastropathy. Consequently, patients often are treated with antacids and gastrointestinal protectants. This therapeutic regimen is based on documented gastric lesions in uremic humans and dogs, but the nature and incidence of uremic gastropathy in cats are unknown.
HYPOTHESIS/OBJECTIVES: Evaluate uremic gastropathy in CKD cats to facilitate refinement of medical management for gastrointestinal signs.
Thirty-seven CKD cats; 12 nonazotemic cats
Stomachs were evaluated for the presence of classic uremic gastropathy lesions. Histopathologic lesions were compared with serum creatinine concentrations, calcium-phosphorus product (CPP), and serum gastrin concentrations.
Gastric ulceration, edema, and vascular fibrinoid change were not observed. The most important gastric lesions in CKD cats were fibrosis and mineralization. Sixteen CKD cats (43%) had evidence of gastric fibrosis of varying severity and 14 CKD cats (38%) had gastric mineralization. CKD cats were more likely to have gastric fibrosis and mineralization than nonazotemic controls (P = .005 and P = .021, respectively). Only cats with moderate and severe azotemia had gastric mineralization. CPP was correlated with disease severity; severely azotemic CKD cats had significantly higher CPP when compared with nonazotemic controls, and to mildly and moderately azotemic cats (P < .05). Gastrin concentrations were significantly higher in CKD cats when compared with nonazotemic controls (P = .003), but increased concentrations were not associated with gastric ulceration.
Uremic gastropathy in CKD cats differs from that described in other species and this difference should be considered when devising medical management.
猫慢性肾病(CKD)与通常归因于尿毒症性胃病的胃肠道症状相关。因此,患者常接受抗酸剂和胃肠道保护剂治疗。这种治疗方案基于尿毒症患者和犬类中已记录的胃部病变,但猫尿毒症性胃病的性质和发生率尚不清楚。
假设/目的:评估CKD猫的尿毒症性胃病,以促进对胃肠道症状的药物治疗优化。
37只CKD猫;12只非氮质血症猫
评估胃中是否存在典型的尿毒症性胃病病变。将组织病理学病变与血清肌酐浓度、钙磷乘积(CPP)和血清胃泌素浓度进行比较。
未观察到胃溃疡、水肿和血管纤维样改变。CKD猫最重要的胃部病变是纤维化和矿化。16只CKD猫(43%)有不同程度的胃纤维化证据,14只CKD猫(38%)有胃矿化。CKD猫比非氮质血症对照组更易出现胃纤维化和矿化(分别为P = 0.005和P = 0.021)。只有中度和重度氮质血症的猫有胃矿化。CPP与疾病严重程度相关;与非氮质血症对照组以及轻度和中度氮质血症猫相比,重度氮质血症CKD猫的CPP显著更高(P < 0.05)。与非氮质血症对照组相比,CKD猫的胃泌素浓度显著更高(P = 0.003),但浓度升高与胃溃疡无关。
CKD猫的尿毒症性胃病与其他物种不同,在制定药物治疗方案时应考虑这种差异。